Helena A Yu1,2, Camelia S Sima3, Matthew D Hellmann1,2, Jarushka Naidoo1, Natalie Busby1, Katherine Rodriguez1, Gregory J Riely1,2, Mark G Kris1,2. 1. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Weill Cornell Medical College, New York, New York. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Prognostic variables are independently associated with survival and are fundamental to clinical trial design. In the current study, the authors evaluated the impact of stage of disease at the time of the initial diagnosis on overall survival (OS) in 2 independent, oncogene-defined cohorts. METHODS: All patients with epidermal growth factor receptor (EGFR)-mutant and KRAS-mutant metastatic lung adenocarcinomas were identified through routine molecular testing from January 2005 through January 2011. Clinical characteristics were obtained. OS from the date of diagnosis of recurrent or de novo metastatic disease was estimated using the Kaplan-Meier method. RESULTS: A total of 635 patients with KRAS-mutant and 496 patients with EGFR-mutant metastatic lung adenocarcinomas were identified. Among patients with KRAS-mutant lung adenocarcinomas, those with de novo metastatic disease were found to have a shorter median OS compared with those with recurrent metastatic disease (13 months vs 18 months; P = .003). In a multivariable analysis of patients with KRAS-mutant lung adenocarcinomas, de novo metastatic disease at the time of diagnosis (TNM stage IV vs stage I-III: hazard ratio, 1.5 [95% confidence interval, 1.2-1.8]; P<.001) was independently associated with shorter OS. In patients with EGFR-mutant lung adenocarcinomas, after controlling for age and Karnofsky performance status, de novo metastatic disease at the time of diagnosis (stage IV vs stage I-III: hazard ratio, 1.3 [95% confidence interval, 1.0-1.7]; P = .03) was found to be independently associated with shorter OS. CONCLUSIONS: Among patients with KRAS-mutant lung adenocarcinomas, stage of disease at diagnosis was associated with OS from the time of diagnosis of recurrent/metastatic disease. In multivariable analyses, in both patients with EGFR-mutant and KRAS-mutant lung adenocarcinomas, advanced stage at the time of diagnosis was found to be independently associated with shorter survival. Stage at diagnosis is a prognostic variable that should be accounted for in prospective studies in patients with metastatic lung adenocarcinomas.
BACKGROUND: Prognostic variables are independently associated with survival and are fundamental to clinical trial design. In the current study, the authors evaluated the impact of stage of disease at the time of the initial diagnosis on overall survival (OS) in 2 independent, oncogene-defined cohorts. METHODS: All patients with epidermal growth factor receptor (EGFR)-mutant and KRAS-mutant metastatic lung adenocarcinomas were identified through routine molecular testing from January 2005 through January 2011. Clinical characteristics were obtained. OS from the date of diagnosis of recurrent or de novo metastatic disease was estimated using the Kaplan-Meier method. RESULTS: A total of 635 patients with KRAS-mutant and 496 patients with EGFR-mutant metastatic lung adenocarcinomas were identified. Among patients with KRAS-mutant lung adenocarcinomas, those with de novo metastatic disease were found to have a shorter median OS compared with those with recurrent metastatic disease (13 months vs 18 months; P = .003). In a multivariable analysis of patients with KRAS-mutant lung adenocarcinomas, de novo metastatic disease at the time of diagnosis (TNM stage IV vs stage I-III: hazard ratio, 1.5 [95% confidence interval, 1.2-1.8]; P<.001) was independently associated with shorter OS. In patients with EGFR-mutant lung adenocarcinomas, after controlling for age and Karnofsky performance status, de novo metastatic disease at the time of diagnosis (stage IV vs stage I-III: hazard ratio, 1.3 [95% confidence interval, 1.0-1.7]; P = .03) was found to be independently associated with shorter OS. CONCLUSIONS: Among patients with KRAS-mutant lung adenocarcinomas, stage of disease at diagnosis was associated with OS from the time of diagnosis of recurrent/metastatic disease. In multivariable analyses, in both patients with EGFR-mutant and KRAS-mutant lung adenocarcinomas, advanced stage at the time of diagnosis was found to be independently associated with shorter survival. Stage at diagnosis is a prognostic variable that should be accounted for in prospective studies in patients with metastatic lung adenocarcinomas.
Authors: Hiroshi Sugimura; Francis C Nichols; Ping Yang; Mark S Allen; Stephen D Cassivi; Claude Deschamps; Brent A Williams; Peter C Pairolero Journal: Ann Thorac Surg Date: 2007-02 Impact factor: 4.330
Authors: William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus Journal: Proc Natl Acad Sci U S A Date: 2004-08-25 Impact factor: 11.205
Authors: William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold E Varmus Journal: PLoS Med Date: 2005-01-25 Impact factor: 11.069
Authors: Nathaniel J Myall; Solomon Henry; Douglas Wood; Joel W Neal; Summer S Han; Sukhmani K Padda; Heather A Wakelee Journal: Clin Lung Cancer Date: 2018-10-23 Impact factor: 4.785
Authors: Valentine M Macaulay; Mark R Middleton; S Gail Eckhardt; Charles M Rudin; Rosalyn A Juergens; Richard Gedrich; Sven Gogov; Sean McCarthy; Srinivasu Poondru; Andrew W Stephens; Shirish M Gadgeel Journal: Clin Cancer Res Date: 2016-02-01 Impact factor: 12.531
Authors: Farastuk Bozorgmehr; Daniel Kazdal; Inn Chung; Martina Kirchner; Nikolaus Magios; Mark Kriegsmann; Michael Allgäuer; Laura V Klotz; Thomas Muley; Rami A El Shafie; Jürgen R Fischer; Martin Faehling; Albrecht Stenzinger; Michael Thomas; Petros Christopoulos Journal: Front Oncol Date: 2021-04-09 Impact factor: 6.244
Authors: Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Debra P Ritzwoller Journal: JNCI Cancer Spectr Date: 2018-06-28
Authors: David Fisch; Farastuk Bozorgmehr; Daniel Kazdal; Jonas Kuon; Laura V Klotz; Rajiv Shah; Florian Eichhorn; Mark Kriegsmann; Marc A Schneider; Thomas Muley; Albrecht Stenzinger; Helge Bischoff; Petros Christopoulos Journal: Front Oncol Date: 2021-07-08 Impact factor: 6.244